Therefore, the present data suggest the pro-steatotic function of GPR55 signaling in hepatocytes and provide a potential therapeutic target for non-alcoholic fatty liver disease. This evidence concerns the gene GPR55 and metabolic dysfunction-associated steatotic liver disease.